Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug dupilumab may lift anxiety and depression

NCT ID NCT07467564

Recruiting now Symptom relief Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 184 people with moderate-to-severe atopic dermatitis (eczema) who are already starting dupilumab treatment. Over six months, researchers will measure changes in anxiety, depression, and quality of life using standard questionnaires. The goal is to see if treating the skin condition also improves mental health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dupilumab
What this could lead to
If successful, this could show that treating eczema with dupilumab also eases anxiety and depression, improving overall well-being.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also limited to Gulf countries and a moderate size of 184 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NMC Specialty Hospital LTD

    RECRUITING

    Abu Dhabi, United Arab Emirates

  • Saudi Medical Services (Medical Fakeeh)

    RECRUITING

    Jeddah, 21331, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.